Management of Transfusional Chronic Iron Overload: Focus on Deferasirox

Most patients with hereditary or chronic acquired anemias are dependent on regular red cell transfusions. Untreated iron overload from transfusions is responsible for morbidity and mortality in patients with thalassemia major. However, clinical consequences of parenchymal iron overload have been rep...

Full description

Saved in:
Bibliographic Details
Published inClinical Medicine Insights: Therapeutics Vol. 1; p. 735
Main Authors Pilo, Federica, Di Tucci, Anna Angela, Dessì, Laura, Angelucci, Emanuele
Format Book Review Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2009
Sage Publications Ltd
Subjects
iron chelation
thalassemia
review
MDS deferasirox
Online AccessGet full text

Cover

More Information
Summary:Most patients with hereditary or chronic acquired anemias are dependent on regular red cell transfusions. Untreated iron overload from transfusions is responsible for morbidity and mortality in patients with thalassemia major. However, clinical consequences of parenchymal iron overload have been reported not only in thalassemia major but also in patients with myelodysplastic syndrome. The current standard in iron chelation therapy is deferoxamine mesylate (Desferal®). Deferasirox is the first oral iron chelator approved in the Europe Union for use in patients with transfusional iron overload with different diseases. The aim of this review is to examine the properties and management of Deferasirox.
ISSN:1179-1713
1179-559X
1179-1713
DOI:10.4137/CMT.S1970